COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Nextech3D.ai Reports $5 Million in 2023 Revenue, Growth Up +56% Preliminary Unaudited Results
Nextech3D.AI (OTCQX:NEXCF)(CSE:NTAR)(FSE:1SS) announces preliminary unaudited financial and operating results for full year 2023, showing strong annual revenue growth of 56% to $5 million. CEO projects even stronger gains in 2024 with major AI technology and contracts for 3D modeling business -
-
COMMUNIQUÉ DE PRESSE
TUI AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
TUI AG issues notification of major holdings under Article 40, Section 1 of the WpHG [German Securities Trading Act] with the aim of Europe-wide distribution. The Goldman Sachs Group, Inc. has acquired/disposed shares and instruments, resulting in a change of breakdown of voting rights -
COMMUNIQUÉ DE PRESSE
Custodian Property Income REIT plc: Directors’ purchase of ordinary shares
Custodian Property Income REIT plc (LSE: CREI) announces purchase of ordinary shares by Independent Non-Executive Directors. Details of the transactions and the Directors' interests in ordinary shares disclosed as required by Market Abuse Regulations -
COMMUNIQUÉ DE PRESSE
Dr. Michael Jewett Joins Theralase(R) to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
Theralase® Technologies Inc. announces the addition of Dr. Michael Jewett as an independent consultant to assist in completing enrollment of patients in the Phase II NMIBC CIS clinical study. Dr. Jewett's expertise will help achieve regulatory approval -
COMMUNIQUÉ DE PRESSE
Signal Gold Announces Final Drill Results of Growth Exploration Program, Including 76.31 g/t Over 0.5 Metres and 12.88 g/t Over 0.6 Metres
Signal Gold Inc. announces final diamond drill results from growth exploration program at Goldboro Project in Nova Scotia, demonstrating continuous gold mineralization and potential for further discovery -
COMMUNIQUÉ DE PRESSE
AmplifyBio CEO J. Kelly Ganjei Discusses Solutions for Reducing Costs and Risk in Advanced Therapy Manufacturing During Fireside Chat at Advanced Therapies Week
J. Kelly Ganjei, CEO of AmplifyBio, shared insights at Advanced Therapies Week on the evolution of manufacturing strategies and fundraising in cell and gene therapy development. The fireside chat panel discussed early commercialization, tech transfer, and AmplifyBio's hybrid outsourcing model -
-
COMMUNIQUÉ DE PRESSE
Celebrating Its Fifth Anniversary, Genesis Reference Laboratories Announces Testing Upgrades
Genesis Reference Laboratories announces upgrades to testing menus, offering more individualized options. The improved menus aim to provide competitive testing while promoting responsible use of healthcare dollars
